Toll-like receptors and ischemic brain injury

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 5, 2014, Pages 378-386

  Gesuete, Raffaella ^a   Kohama, Steven G ^b   Stenzel Poore, Mary P ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cerebral ischemia; Ischemic brain injury; Preconditioning; Stroke; Toll like receptors

Indexed keywords

INTERFERON; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

BLOOD BRAIN BARRIER; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW;

ANIMALS; BRAIN ISCHEMIA; HUMANS; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84899586313     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000068     Document Type: Review

References (69)

1. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008;55:310-18
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics V2012 update: A report from the American Heart Association. Circulation 2012;125:e2-220
3. Carpenter CR, Keim SM, Milne WK, et al. Thrombolytic therapy for acute ischemic stroke beyond three hours. J Emerg Med 2011;40:82-92
4. Shobha N, Buchan AM, Hill MD. Thrombolysis at 3Y4.5 hours after acute ischemic stroke onset-evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) Registry. Cerebrovasc Dis 2011;31:223-28
5. Shichita T, Ago T, Kamouchi M, et al. Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke. J Neurochem 2012;123(Suppl 2):29-38
6. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009; 158:1007-20
7. Vartanian KB, Stenzel-Poore MP. Toll-like receptor tolerance as a mechanism for neuroprotection. Transl Stroke Res 2010;1:252-60
8. Barber PA, Hach S, Tippett LJ, et al. Cerebral ischemic lesions on diffusion-weighted imaging are associated with neurocognitive decline after cardiac surgery. Stroke 2008;39:1427-33
9. Adams HPJ. Ischemic cerebrovascular complications of cardiac procedures. Circulation 2010;121:846-47
10. Kahlert P, Al-Rashid F, Dottger P, et al. Cerebral embolization during transcatheter aortic valve implantation: A transcranial Doppler study. Circulation 2012;126:1245-55
11. Mallard C. Innate immune regulation by toll-like receptors in the brain. ISRN Neurol 2012;2012:701950
12. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010;11:373-84
13. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006;7:49-56
14. Song DH, Lee JO. Sensing of microbial molecular patterns by Toll-like receptors. Immunol Rev 2012;250:216-29
15. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801
16. Ostuni R, Zanoni I, Granucci F. Deciphering the complexity of Toll-like receptor signaling. Cell Mol Life Sci 2010;67:4109-34
17. Qian C, Cao X. Regulation of Toll-like receptor signaling pathways in innate immune responses. Ann N Y Acad Sci 2013;1283:67-74
18. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511
19. Brown J, Wang H, Hajishengallis GN, et al. TLR-signaling networks: An integration of adaptor molecules, kinases, and cross-talk. J Dent Res 2011;90:417-27
20. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010; Article ID 672395. doi:10.1155/2010/672395
21. Iadecola C, Anrather J. The immunology of stroke: From mechanisms to translation. Nat Med 2011;17:796-808
22. Hanisch UK, Johnson TV, Kipnis J. Toll-like receptors: Roles in neuroprotection? Trends Neurosci 2008;31:176-82
23. Qiu J, Nishimura M, Wang Y, et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008;28:927-38
24. Zhang J, Takahashi HK, Liu K, et al. Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 2011;42:1420-28
25. Muhammad S, Barakat W, Stoyanov S, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008;28:12023-31
26. Liu K, Mori S, Takahashi HK, et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007;21:3904-16
27. Patenaude A, Murthy MR, Mirault ME. Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cell Mol Life Sci 2005;62: 1063-80
28. Rashidian J, Rousseaux MW, Venderova K, et al. Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo. J Neurosci 2009;29:12497-505
29. Shichita T, Hasegawa E, Kimura A, et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 2012;18:911-17
30. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci 2007;104:13798-803
31. Lehnardt S, Lehmann S, Kaul D, et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007;190:28-33
32. Ziegler G, Harhausen D, Schepers C, et al. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun 2007;359:574-79
33. Hua F, Ma J, Ha T, et al. Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 2009; 1262:100-8
34. Bohacek I, Cordeau P, Lalancette-Hebert M, et al. Toll-like receptor 2 deficiency leads to delayed exacerbation of ischemic injury. J Neuroinflamm 2012;9:191
35. Cao CX, Yang QW, Lv FL, et al. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficientmice. Biochem Biophys Res Commun 2007;353:509-14
36. Caso JR, Pradillo JM, Hurtado O, et al. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007;115:1599-608
37. Hyakkoku K, Hamanaka J, Tsuruma K, et al. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010;171:258-67
38. Reismann P, Lichy C, Rudofsky G, et al. Lack of association between polymorphisms of the toll-like receptor 4 gene and cerebral ischemia. J Neurol 2004;251:853-58
39. Lin YC, Chang YM, Yu JM, et al. Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis 2005;180:305-9
40. Brea D, Blanco M, Ramos-Cabrer P, et al. Toll-like receptors 2 and 4 in ischemic stroke: Outcome and therapeutic values. J Cereb Blood Flow Metab 2011;31:1424-31
41. Urra X, Villamor N, Amaro S, et al. Monocyte subtypes predict clinical course and prognosis in human stroke. J Cereb Blood Flow Metab 2009; 29:994-1002
42. Yang QW, Li JC, Lu FL, et al. Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab 2008;28:1588-96
43. Wu D, Lee YC, Liu HC, et al. Identification of TLR downstream pathways in stroke patients. Clin Biochem 2013;46:1058-64
44. Brea D, Sobrino T, Rodriguez-Yanez M, et al. Toll-like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory response in acute ischemic stroke. Clin Immunol 2011;139:193-98
45. Dirnagl U, Becker K, Meisel A. Preconditioning and tolerance against cerebral ischaemia: From experimental strategies to clinical use. Lancet Neurol 2009;8:398-412
46. Pradillo JM, Fernandez-Lopez D, Garcia-Yebenes I, et al. Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. J Neurochem 2009;109:287-94
47. Hua F, Ma J, Ha T, et al. Preconditioning with a TLR2 specific ligand increases resistance to cerebral ischemia/reperfusion injury. J Neuroimmunol 2008;199:75-82
48. Leung PY, Stevens SL, Packard AE, et al. Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. Stroke 2012;43:1383-89
49. Packard AE, Hedges JC, Bahjat FR, et al. Poly-IC preconditioning protects against cerebral and renal ischemia-reperfusion injury. J Cereb Blood Flow Metab 2012;32:242-47
50. Stevens SL, Ciesielski TM, Marsh BJ, et al. Toll-like receptor 9: A new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab 2008;28:1040-47
51. Tasaki K, Ruetzler CA, Ohtsuki T, et al. Lipopolysaccharide pretreatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 1997;748:267-70
52. Rosenzweig HL, Minami M, Lessov NS, et al. Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: A novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab 2007;27:1663-74
53. Stevens SL, Leung PY, Vartanian KB, et al. Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci 2011;31: 8456-63
54. Marsh B, Stevens SL, Packard AE, et al. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: A critical role for IRF3. J Neurosci 2009;29:9839-49
55. Longhi L, Gesuete R, Perego C, et al. Long-lasting protection in brain trauma by endotoxin preconditioning. J Cereb Blood Flow Metab 2011; 31:1919-29
56. Pappas DJ, Gabatto PA, Oksenberg D, et al. Transcriptional expression patterns triggered by chemically distinct neuroprotective molecules. Neuroscience 2012;226:10-20
57. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med 2002;8:1363
58. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: Secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004;21:461-65
59. Gesuete R, Packard AE, Vartanian KB, et al. Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling. J Neurochem 2012;123(Suppl 2):75-85
60. Bsibsi M, Ravid R, Gveric D, et al. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002;61:1013-21
61. Constantin D, Cordenier A, Robinson K, et al. Neisseria meningitidis-induced death of cerebrovascular endothelium: Mechanisms triggering transcriptional activation of inducible nitric oxide synthase. J Neurochem 2004;89:1166-74
62. Fil D, Borysiewicz E, Konat GW. A broad upregulation of cerebral chemokine genes by peripherally-generated inflammatory mediators. Metab Brain Dis 2011;26:49-59
63. Packard AE, Leung PY, Vartanian KB, et al. TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning. J Cereb Blood Flow Metab 2012;32:2193-200
64. Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun 2007;21:727-35
65. Veighey K, Macallister RJ. Clinical applications of remote ischemic preconditioning. Cardiol Res Pract 2012;2012:620681
66. Hoole SP, Heck PM, Sharples L, et al. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: A prospective, randomized control trial. Circulation 2009;119:820-27
67. Meng R, Asmaro K, Meng L, et al. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology 2012; 79:1853-61
68. Bahjat FR, Williams-Karnesky RL, Kohama SG, et al. Proof of concept: Pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. J Cereb Blood Flow Metab 2011;31:1229-42
69. Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1: 894-907